Sector News

DSM and Amyris ink development deal

July 18, 2017
Chemical Value Chain

Industrial bioscience firm Amyris (Emeryville, California) announced on Monday that it has entered into its first product development and production agreement with DSM.

The agreement covers an undisclosed food and nutrition molecule for which DSM is a major market provider. DSM will fund technology development, and Amyris will scale and supply the ingredient in the long-term.

The agreement is expected to be the first of many such collaborations, Amyris says. In May, DSM made an initial equity investment in Amyris of $25 million for a shareholding of about 12%. Subject to certain conditions, DSM could invest an additional $25 million in the company within 90 days of the first tranche if approved by DSM’s board. As part of the deal, DSM and Amyris agreed to collaborate on a number of short- to medium-term product development and production opportunities using Amyris’s yeast-based strain engineering platform.

By Rebecca Coons

Source: Chemical Week

comments closed

Related News

July 3, 2022

Neste acquires European rights to Alterra’s chemical recycling tech for difficult plastics

Chemical Value Chain

Neste has bought the European rights for Alterra Energy’s liquefaction technology, strengthening its chemical recycling capabilities. Alterra is a US-based company that has developed a thermochemical solution for liquefying difficult-to-recycle plastics.

July 3, 2022

Maria Soler Nunez appointed as Head, Group Operations at Lonza

Chemical Value Chain

Lonza appoints Maria Soler Nunez as Head, Group Operations. Maria joins Lonza from Novartis where she has led the quality organization since 2020. Maria will commence her tenure with Lonza Group on 1 August 2022, succeeding Stefan Stoffel, who is retiring from Lonza.

July 3, 2022

AkzoNobel announces Gregoire Poux-Guillaume as new Chief Executive Officer as of November 1, 2022

Chemical Value Chain

AkzoNobel has announced that Gregoire Poux-Guillaume will become the company’s new Chief Executive Officer (CEO) as of November 1, 2022. He will succeed Thierry Vanlancker, who has been CEO and member of the Board of Management since 2017, and whose term of office is coming to an end.